AI English summary of an SEC filing — figures as filed
Agilent Technologies AThe company said net revenue for 2024 fiscal year was $6,510 million, down 5% from 2023. It said revenue in life sciences and applied markets fell 8%, revenue in diagnostics and genomics fell 6%, and revenue in Agilent CrossLab rose 5%.
Key points
AI summaryThe company said net revenue for 2024 fiscal year was $6,510 million, down 5% from 2023. It said revenue in life sciences and applied markets fell 8%, revenue in diagnostics and genomics fell 6%, and revenue in Agilent CrossLab rose 5%.
Agilent said on September 20, 2024 it acquired 100% of the stock of BIOVECTRA for total cash consideration of $915 million. The company also said it issued senior notes on September 9, 2024 in aggregate principal amounts of $600 million each, maturing in 2027 (4.20%) and 2034 (4.75%).
The company said net cash provided by operating activities for fiscal 2024 was $1,751 million (2023: $1,772 million). As of October 31, 2024, cash and cash equivalents were $1,329 million, compared with $1,590 million as of October 31, 2023.
The company said it repurchased and retired 8.4 million shares for $1,150 million, excluding excise taxes, in fiscal 2024. As of October 31, 2024, remaining authorization under the 2023 repurchase program was approximately $374 million. Cash dividends for the same year were $0.944 per share, or $274 million in total.
Key figures
Fiscal year ended October 31, 2024
- Revenue
- $6.5B
- Operating income
- $1.5B
- Net income
- $1.3B
- EPS
- $4.43
- Operating cash flow
- $1.8B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Fiscal 2024 Revenue and Segment Changes
The company said net revenue for 2024 fiscal year was $6,510 million, down 5% from 2023. It said revenue in life sciences and applied markets fell 8%, revenue in diagnostics and genomics fell 6%, and revenue in Agilent CrossLab rose 5%.
Source · Based on the MD&A text of the filing
BIOVECTRA Acquisition and Senior Notes
Agilent said on September 20, 2024 it acquired 100% of the stock of BIOVECTRA for total cash consideration of $915 million. The company also said it issued senior notes on September 9, 2024 in aggregate principal amounts of $600 million each, maturing in 2027 (4.20%) and 2034 (4.75%).
Source · Based on the MD&A text of the filing
Fiscal 2024 Operating Cash Flow and Cash Balance
The company said net cash provided by operating activities for fiscal 2024 was $1,751 million (2023: $1,772 million). As of October 31, 2024, cash and cash equivalents were $1,329 million, compared with $1,590 million as of October 31, 2023.
Source · Based on the MD&A text of the filing
Share Repurchases and Dividends
The company said it repurchased and retired 8.4 million shares for $1,150 million, excluding excise taxes, in fiscal 2024. As of October 31, 2024, remaining authorization under the 2023 repurchase program was approximately $374 million. Cash dividends for the same year were $0.944 per share, or $274 million in total.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…